Study identifier:D9612L00107
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
An Open-Label, Exploratory Trial to Assess Gastric Acid Control in Critically Ill Subjects Receiving Nexium I.V. (esomeprazole sodium) 40mg BID for up to 72 hours
Gastric Ulcer
Phase 4
No
Esomeprazole Sodium
All
40
Interventional
18 Years +
Allocation: Non-randomized 
Endpoint Classification: Pharmacodynamics Study 
Intervention Model: Single Group Assignment 
Masking: Open Label 
Primary Purpose: Treatment 
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
| Arms | Assigned Interventions | 
|---|